Comparison Of 24-Hour FEV1 Profile For Once-Daily Versus Twice-Daily Treatment With Olodaterol, A Novel Long-Acting B2-Agonist, In Patients With COPD - Concepedia

Concepedia

Publication | Closed Access

Comparison Of 24-Hour FEV1 Profile For Once-Daily Versus Twice-Daily Treatment With Olodaterol, A Novel Long-Acting B2-Agonist, In Patients With COPD

10

Citations

0

References

2012

Year

Guy Joos, Joseph Aumann, Carl Coeck, Lawrence Korducki, Alan Hamilton, J.A. van Noord

Unknown Venue

Pulmonary Care24-Hour Fev1 ProfilePulmonary MedicinePharmacotherapyMedicinePulmonary Disease

No additional data available for this publication yet. Check back later!